Abstract
IntroductionAtezolizumab is a programmed death ligand-1 inhibitor for urothelial bladder cancer treatment. Atezolizumab has become the standard therapy for patients with urothelial bladder cancer who are not responding to cisplatin-based...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have